An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the ...

Eli Lilly's (LLY) experimental obesity drug, eloralintide, shows up to 11% weight loss in 12 weeks with minimal side effects in early-stage trial. Read more here.

Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick ...

Eli Lilly ( LLY 0.36%) has been a great growth pick for investors over the past few years. The pharma company, thanks to its ...

Global drugmakers, including generic drug manufacturers in India, are racing to develop their versions of blockbuster ...

The appointments include Caroline Thompson as centre manager, and Dr Becky Sage and Dr Kam Pooni as entrepreneurs in residence (EiRs). They join this month as part of Bristol Innovations, the ...

Lilly Sabri used to hope at least three people would show up to her Pilates classes, now she has six million YouTube ...

Dr. Robert Holub, 41, left, recently joined the Alzheimer’s research practice of his father, Dr. Richard Holub, 77, ...

IUS ETF's unique value tilt with a business-size weighting approach offers sector diversity and strong returns.

Looking at licensing deals struck in the past 10 years, Jefferies found that many Big Pharmas do not ultimately follow ...

The market seems to share this optimistic view, since Eli Lilly and has a short interest of only 0.9% (this is the percentage ...